Readouts for two late-stage, potentially registrational trials of nemvaleukin alfa expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal melanoma Preliminary ...
We are pleased to expand commercial access to QUELIMMUNE and are extremely proud to be the only company to develop and commercialize a therapeutic device that has demonstrated clinical results to ...